Piper Jaffray increases its price target on Overweight-rated MAKO Surgical Corp
MAKO to $50, up $13, reflecting potential catalysts and fundamentals that should provide support to the company.
Piper Jaffray says, "WE see potential positive catalysts including the potential approval of the new hip and new hospital network contracts. We also see compelling fundamental support for further upside, and we include in this report our updated scenario and discounted cash flow analysis as supplementary support for our investment thesis."
MAKO closed at $38.83 a share on Friday.
Loading...
Loading...
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in